Roquefort Therapeutics Advances Prostate Cancer Trial and Extends AO-252 License Agreement

Roquefort refocuses AO-252 on prostate cancer, doses first mCRPC patient, and extends its key license agreement to March 2026.

12 December 2025by Joshua Thompson5 min read51 views

This article covers information on Roquefort Therapeutics PLC.

LON:ROQ

Roquefort pushes AO-252 into prostate cancer while tweaking deal terms

Roquefort Therapeutics has tightened its focus on prostate cancer for AO-252 and extended the deadline on its licensing deal with Coiled Therapeutics (Coiled USA) and A2A Pharmaceuticals. There’s real clinical momentum here, alongside some bigger numbers on the equity consideration. Here’s what’s changed, why it matters, and what to watch next.

Phase I clinical update: first mCRPC patient dosed, broader enrolment unlocked

Coiled USA has secured a protocol amendment to widen its Phase I inclusion criteria to all solid tumours, including patients with or without brain metastases. That matters because AO-252 is described as brain-penetrant, and broader eligibility can speed recruitment and build a richer safety and activity picture.

Crucially, Coiled USA has now prioritised prostate cancer as the lead indication. The first patient with metastatic castration-resistant prostate cancer (mCRPC) was enrolled and dosed in November 2025 in “Cohort 4b” – the dose level within a six-cohort escalation where the strongest clinical benefit has been seen so far. A “food effect” cohort study at the 4b dose has also started, using PK/PD modelling (that’s pharmacokinetics/pharmacodynamics – how the drug moves through and acts in the body) to optimise exposure.

Pre-clinical signal looks supportive for prostate cancer

Roquefort highlights several pre-clinical datasets that back the pivot:

VCaP xenografts (AR-positive, ETS-fusion): 100% complete/partial response with complete regressions observed.
AR-independent cell lines: 60% tumour growth inhibition (TGI).
22Rv1 models (AR-resistant): 90% TGI.
Mechanism: efficacy observed independent of androgen signalling – useful in resistant disease.

Early Phase I signals are characterised as encouraging on safety, with the best activity to date seen at the Cohort 4b dose. As ever, pre-clinical success doesn’t guarantee clinical efficacy, but the package is directionally positive for mCRPC.

AO-252: what it is

AO-252 is a novel, brain-penetrant small molecule designed to disrupt TACC3 protein-protein interactions. Coiled USA is running the Phase I trial in the US (trial ID: NCT06136884). The trial is actively enrolling to assess safety and early signs of efficacy in patients whose cancers have progressed on other treatments.

Share𝕏 in

Investing
Polar Capital Technology Trust Reports 102% NAV Growth in Stellar Fiscal Year
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Investing

Tagged

Last updated

5 July 2026

Star Rating

No ratings yet

Sector read-across: J&J’s US$3.05 billion Halda deal

Roquefort points to Johnson & Johnson’s US$3.05 billion cash acquisition of Halda Therapeutics OpCo (announced 17 November 2025) as fresh validation of appetite for oral targeted therapies in prostate cancer. Halda’s Phase I/II showed preliminary efficacy and a strong early safety profile. Different assets, of course, but the cheque size shows big pharma is shopping in this space.

License extension to 16 March 2026 and revised terms

The AO-252 License Agreement completion requires Roquefort’s enlarged share capital to be admitted to trading on AIM by a “Longstop Date”. That date moves from 31 January 2026 to 16 March 2026, reflecting holiday-season timing and to allow extra time for data readouts. The AIM Admission Document will be published in due course.

In exchange for the extension, the commercial terms are amended. The upfront consideration rises, and the deferred equity structure for A2A Pharma is reset via market capitalisation hurdles.

Key deal economics at a glance

Longstop Date	Extended to 16 March 2026 (from 31 January 2026)
Upfront consideration	£31,875,000 in Ordinary Shares
Effective issue price	1.7 pence per share
Indicative number of Consideration Shares	1,875,000,000 shares (derived from value and price), subject to Admission
Deferred Consideration Shares	– 250,000,000 if market cap ≥ £60 million (30 consecutive days) – Additional 250,000,000 if ≥ £90 million – Additional 250,000,000 if ≥ £120 million
Trial status	Phase I ongoing in the US; first mCRPC patient dosed in Cohort 4b (Nov 2025); food effect cohort initiated
Inclusion criteria	Expanded to all solid tumours, including patients with or without brain metastases

Why this update matters for Roquefort shareholders

Positive takeaways

Clearer clinical strategy: focusing on mCRPC should sharpen development, partnering and investor messaging.
Early signal where it counts: strongest benefit seen at Cohort 4b, now the active dose for more patients and a food effect study. That’s a pragmatic way to tune exposure early.
Category momentum: the J&J-Halda deal underscores appetite for oral targeted prostate cancer drugs with clean safety and early efficacy.
More time for data: extending the Longstop Date gives room for additional readouts to support Admission and the Transaction.

Balancing considerations

Equity-heavy structure: the higher upfront consideration is entirely in shares. At an effective 1.7 pence, it equates to about 1.875 billion new shares, subject to Admission. The current share count isn’t disclosed here, so the dilution percentage cannot be assessed from this RNS.
Further dilution possible: up to 750 million Deferred Consideration Shares could be issued if market cap hurdles are met.
Execution risk: Admission to AIM is a condition and is not guaranteed. The timeline has slipped to mid-March 2026.
Clinical stage risk: Phase I is primarily designed to assess safety and find the right dose. Pre-clinical wins don’t always translate in humans.

Management commentary: confidence backed by signals

Chairman Stephen West frames the move to prostate cancer as aligned with feedback from potential partners and investors, alongside supportive pre-clinical data. He also calls out the J&J/Halda deal as real-world validation of the opportunity for novel oral therapies in prostate cancer.

Proposed CEO Dr Sridhar Vempati highlights Cohort 4b as the dose level with “the most meaningful activity, including tumour reduction” and emphasises the food effect study to maximise bioavailability. Both statements point to a data-led, dose-optimisation push ahead of wider expansion.

What to watch next

Recruitment cadence and any early activity/safety updates in Cohort 4b mCRPC patients.
Readout from the food effect cohort – clarity on exposure could shape dosing and future efficacy signals.
Publication of the AIM Admission Document and progress toward Admission by 16 March 2026.
Any partnering interest or additional validation as the dataset builds.

Bottom line

This is a sensible sharpening of the AO-252 story: a broadened Phase I, a defined bet on prostate cancer, and extra time to bring more data to the table before closing the Transaction. The flip side is greater equity issuance risk, both upfront and via market cap milestones, with Admission still to be delivered.

If AO-252 continues to show encouraging safety and activity at Cohort 4b, the commercial logic strengthens – especially in light of recent sector M&A. For now, eyes on recruitment, the food effect readout, and the AIM timetable.